Comment from Anonymous

Public Comment Submission for Docket FDA-2025-P-6831 To: FDA Commissioner Marty Makary / Center for Biologics Evaluation and Research (CBER) Subject: Submission of Evidence Regarding Spike-Induced Fibrinaloid Formation and Vascular Pathogenesis; Request for Administrative Stay. I. Executive Summary The FDA is required under the Administrative Procedure Act to evaluate emerging safety data that alters the risk-benefit profile of authorized biological products. This submission provides evidence of a definitive molecular mechanism for vascular injury: "SARS-CoV-2 Spike Protein Amyloid Fibrils Impair Fibrin Formation and Fibrinolysis" (Westman, Hammarström, & Nyström, 2026). Data confirm the SARS-CoV-2 spike protein—the primary antigen produced by mRNA and viral vector platforms—is inherently amyloidogenic. II. Spike 685 as a Pathogenic Agent The Westman et al. research isolates a peptide segment, Spike 685, which initiates misfolding of fibrinogen into dense, amyloid-like fibrils. These structures differ from standard physiological clots and are characterized by extreme resistance to plasmin-mediated fibrinolysis. Consequently, endogenous mechanisms intended to dissolve thrombi are inhibited, leading to persistent microvascular occlusion. This structural alteration of blood proteins represents a failure in product safety not addressed during clinical trials. III. Documented Pathways of Pathogenesis The following 16 pathways describe a mechanism of systemic injury and vascular degradation supported by the Westman study and biochemical literature: P1: Heparin-displacement and ternary complexes – Disruption of endogenous anticoagulation regulation. P2: Spike-induced amyloid-like fibrin – Formation of insoluble, non-degradable microclots. P3: Protein–polyanion coacervates – Scaffolded coagulation driven by charge-based protein aggregation. P4: Immune complex and PF4-mediated platelet activation – Direct triggering of thrombotic thrombocytopenia pathways. P5: Endothelial activation and complement amplification – Sustained vascular inflammation and basement membrane damage. P6: NETosis and histone-mediated thrombosis – Neutrophil-driven clotting resulting in tissue necrosis. P7: Platelet microparticle seeding – Systemic dissemination of pro-thrombotic signals. P8: Extracellular vesicle (EV) transport of Spike – Bio-distribution of spike protein to distal organs, including the heart and CNS. P9: Complement-opsonized aggregate formation – Accumulation of protein aggregates in the microvasculature. P10: Protease-mediated fibrin remodeling – Formation of resistant fragments that evade metabolic clearance. P11: Lipid nanoparticle (LNP)-protein aggregation – Instability in the delivery vehicle contributing to off-target effects. P12: Antibody-mediated crosslinking – Formation of circulating immune complexes causing Type III hypersensitivity. P13: Endotoxin-triggered coagulation – Synergy between spike protein and circulating lipopolysaccharides. P14: Oxidative stress-induced endothelial damage – Accelerated degradation of the vascular endothelium. P15: Protein misfolding and heterologous amyloid seeding – Potential for spike protein to act as a template for systemic amyloidosis. P16: Metal-mediated precipitation – Formation of mixed inorganic-protein particles contributing to vascular obstruction. IV. Mandatory Regulatory Requirements The identification of Spike 685-induced amyloidosis invalidates the safety profile of all SARS-CoV-2 vaccine products. The FDA cannot ignore evidence of a pro-amyloidogenic toxin produced by regulated products. Administrative Stay: Under 21 CFR 10.35, the FDA must stay the administration of these products while a comprehensive investigation into fibrinolysis resistance is conducted. AEMS Integration: The FDA must cross-reference Westman et al. findings with the Advanced Event Monitoring System (AEMS) to quantify amyloid-related mortality and morbidity. Pathogenesis Review: Regulatory assessments must account for the CD8+ Cytotoxic T-cell response to these amyloid deposits, which facilitates systemic tissue destruction. V. Conclusion Evidence provided by Westman et al. transitions the discussion of vaccine injury to established molecular biochemistry. To dismiss this data is regulatory negligence. The FDA must fulfill its mission to protect public health by suspending these products until risks of irreversible amyloidogenic harm are mitigated.